We are ready to complement the launch of the TAXUS™ product with a steady flow of new products from both our Cardiovascular and Endosurgery groups. This is a testament to the dedication and creativity of our Research & Development organization. They are an integral part of our collaborative approach, and their contributions are evidenced by the more than 20 new product offerings that await U.S. launch in 2003 and beyond. Many have already been introduced in Europe and other international markets.

While the following list is by no means complete, these products represent some of the more promising opportunities for Boston Scientific in the near future. As these technologies continue to move from development or trial stage to launch, we remain focused on improving them and creating new technologies to refill our pipeline. In short, we remain focused on delivering what’s next.